{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-161593","form_type":"8-K","ticker":"TSHA","cik":"0001806310","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2023-06-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.693017+00:00","generated_at":"2026-06-14T06:45:48.296014+00:00","sec_items":["5.02"],"event_type":"other","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Taysha grants performance-based options to CEO (666.5K), President (477.2K), CFO (268K)","bullets":["CEO Sean Nolan receives 666,500 options; President Sukumar Nagendran 477,150; CFO Kamran Alam 267,975.","Awards tied to clinical, regulatory, and corporate milestones by Dec 31, 2023; vest over 3 years.","Board revised director compensation: initial equity grant set at 43,800 shares; annual at 36,200 shares.","Options under 2020 Stock Incentive Plan; intended to strengthen pay-for-performance alignment.","No departure reported; grants are one-time performance-based equity incentives."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-161593","json":"https://secwatch.observer/filing/0001193125-23-161593.json","markdown":"https://secwatch.observer/filing/0001193125-23-161593.md","text":"https://secwatch.observer/filing/0001193125-23-161593.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806310/000119312523161593/0001193125-23-161593-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806310/000119312523161593/d480804d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T06:45:48.296014+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}